Should asymptomatic heart valve patients get surgery now? major trial aims to settle debate
NCT ID NCT03389542
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two approaches for people with a severe leaky heart valve (mitral regurgitation) who have no symptoms yet. Half will get early valve repair surgery, while the other half will be monitored closely every 6 months. The goal is to see which strategy leads to fewer deaths or serious heart problems over 5 years. About 424 participants are being enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- mitral valve repair surgery
- What this could lead to
- If early surgery proves better, it could establish a new standard for treating severe mitral regurgitation before symptoms appear, potentially preventing heart failure and other serious events.
- What could go wrong
- This is an ongoing trial with results not yet available. Surgery always carries risks like infection or complications, and watchful waiting may be equally safe for some patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEGENERATIVE MITRAL REGURGITATION (MR) DUE TO LEAFLET PROLAPSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Amiens-Picardie
RECRUITINGAmiens, 80054, France
-
Centre Cardiologique du Nord
RECRUITINGSaint-Denis, 93200, France